Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / STAT6

STAT6

Basics

Aliases:
This biomarker is also known as:
  • IL-4 Stat,
  • transcription factor IL-4 STAT,
  • IL-4-STAT,
  • STAT6B,
  • signal transducer and activator of transcription 6, interleukin-4 induced,
  • STAT, interleukin4-induced,
  • signal transducer and activator of transcription 6,
  • D12S1644,
  • STAT6C,

View in BioMuta

Description…

STAT6 is a member of the STAT family of transcription factors. STAT family members are phosphorylated by the receptor associated kinases in response to cytokines and growth factors and are involved in signal transduction and activation of transcription. There are several transcript variants produced by alternative splicing.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: STAT6

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: Two
QA State: Under Review

Overview

The transcription factor STAT6 is a member of a family of DNA binding proteins. STAT6 has been shown to be a critical cell differentiation modulator in breast cancer cells.

Performance Comment

STAT6 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.